Galan et al., Pathogens and Global Health, doi:10.1080/20477724.2021.1890887 (Peer Reviewed) Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection
RCT 168 very late stage severe condition hospitalized patients comparing CQ, HCQ, and ivermectin not showing significant differences. Authors were unable to add a control arm due to ethical issues.Authors claim that "the mortality rates of the three groups are very similar to historical reports of other studies that used placebo in hospitalized patients", without providing any reference. However  shows 43% hospital mortality in the northern region of Brazil, where the study was performed, from which we can estimate the mortality with ivermectin in this study is 47% lower, RR 0.53. Further, the study is restricted to more severe cases, hence the expected mortality may be higher.
Galan et al., 3/8/2021, peer-reviewed, 19 authors.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary;
multiple approaches are required to protect all people from all existing and
future variants. We do not provide medical advice. Before taking any
medication, consult a qualified physician who can provide personalized advice
and details of risks and benefits based on your medical history and situation.
Treatment protocols for physicians are available from the FLCCC.